ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 65 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,662,657 | +12.3% | 2,588,869 | +44.1% | 0.00% | – |
| Q2 2023 | $13,944,922 | +48.9% | 1,797,026 | +9.4% | 0.00% | – |
| Q1 2023 | $9,365,522 | +2.8% | 1,643,074 | +6.3% | 0.00% | – |
| Q4 2022 | $9,107,619 | +111.3% | 1,546,285 | +14.8% | 0.00% | – |
| Q3 2022 | $4,310,000 | -31.9% | 1,346,862 | -4.7% | 0.00% | – |
| Q2 2022 | $6,333,000 | -27.9% | 1,413,731 | -14.0% | 0.00% | – |
| Q1 2022 | $8,779,000 | -63.4% | 1,644,019 | +0.9% | 0.00% | -100.0% |
| Q4 2021 | $23,960,000 | -28.3% | 1,630,038 | +1.9% | 0.00% | 0.0% |
| Q3 2021 | $33,433,000 | +53.2% | 1,598,922 | +29.6% | 0.00% | 0.0% |
| Q2 2021 | $21,828,000 | -29.0% | 1,233,870 | -1.7% | 0.00% | 0.0% |
| Q1 2021 | $30,752,000 | +4.7% | 1,255,207 | +44.7% | 0.00% | 0.0% |
| Q4 2020 | $29,366,000 | +175.5% | 867,551 | +103.6% | 0.00% | – |
| Q3 2020 | $10,659,000 | -26.3% | 426,166 | -0.6% | 0.00% | -100.0% |
| Q2 2020 | $14,460,000 | – | 428,714 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |